CL2021000454A1 - Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina - Google Patents

Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina

Info

Publication number
CL2021000454A1
CL2021000454A1 CL2021000454A CL2021000454A CL2021000454A1 CL 2021000454 A1 CL2021000454 A1 CL 2021000454A1 CL 2021000454 A CL2021000454 A CL 2021000454A CL 2021000454 A CL2021000454 A CL 2021000454A CL 2021000454 A1 CL2021000454 A1 CL 2021000454A1
Authority
CL
Chile
Prior art keywords
pyrazol
naphthyridine
methyl
preparing
methylmofolin
Prior art date
Application number
CL2021000454A
Other languages
English (en)
Inventor
Rubenbauer Philipp
Gerardus Gieling Reinerus
Platzek Johannes
Nicolaas Sebastiaan Van Der Haas Hendricus
Elisabeth Hoogeveen Sonja
Cornelis Maria VAN OERS Matthijs
Alexander DEKKER Jeroen
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CL2021000454A1 publication Critical patent/CL2021000454A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un método para preparar 2-[(3R)-3-metilmofolin4-il]-4-(1-metil-1H-pirazol-5-il)-8-(1H-pirazol-5-il)-1,7-naftiridina (“el compuesto de la fórmula (I)” a continuación) así como a compuestos intermedios útiles en la preparación del compuesto de la fórmula (I). La presente invención también cubre la forma polimórfica B del compuesto de la fórmula (I) con una pureza muy alta.
CL2021000454A 2018-08-24 2021-02-23 Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina CL2021000454A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18190731 2018-08-24

Publications (1)

Publication Number Publication Date
CL2021000454A1 true CL2021000454A1 (es) 2021-07-09

Family

ID=63405064

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021000454A CL2021000454A1 (es) 2018-08-24 2021-02-23 Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina

Country Status (27)

Country Link
US (1) US20210253573A1 (es)
EP (1) EP3841101B1 (es)
JP (1) JP7422741B2 (es)
KR (1) KR20210049845A (es)
CN (1) CN112823158B (es)
AU (1) AU2019324521A1 (es)
BR (1) BR112021001309A2 (es)
CA (1) CA3110394A1 (es)
CL (1) CL2021000454A1 (es)
CO (1) CO2021001892A2 (es)
DK (1) DK3841101T3 (es)
ES (1) ES2950825T3 (es)
FI (1) FI3841101T3 (es)
HR (1) HRP20230611T1 (es)
HU (1) HUE062332T2 (es)
IL (1) IL280878A (es)
JO (1) JOP20210032A1 (es)
LT (1) LT3841101T (es)
MX (1) MX2021002132A (es)
PE (1) PE20210862A1 (es)
PL (1) PL3841101T3 (es)
PT (1) PT3841101T (es)
RS (1) RS64362B1 (es)
SG (1) SG11202101011RA (es)
SI (1) SI3841101T1 (es)
UA (1) UA128407C2 (es)
WO (1) WO2020039025A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700283B (zh) 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
US11690911B2 (en) 2017-08-04 2023-07-04 Bayer Aktiengesellschaft Combination of ATR kinase inhibitors and PD-1/PD-L1 inhibitors
US11236070B2 (en) 2019-05-16 2022-02-01 Novartis Ag Chemical process

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101405001A (zh) * 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
JP2010529031A (ja) 2007-05-29 2010-08-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害剤としてのナフチリジン誘導体
EP2342190A1 (en) 2008-09-02 2011-07-13 Novartis AG Bicyclic kinase inhibitors
KR101953210B1 (ko) 2011-05-19 2019-02-28 푼다시온 센트로 나시오날 드 인베스티가시오네스 온콜로기카스 카를로스Ⅲ 단백질 키나아제 억제제로서의 대환식 화합물
KR101366368B1 (ko) * 2011-07-08 2014-02-21 주식회사 두산 신규 유기 전계 발광 화합물 및 이를 포함하는 유기 전계 발광 소자
TWI700283B (zh) * 2014-08-04 2020-08-01 德商拜耳製藥公司 ２-(嗎啉-４-基)-１,７-萘啶
WO2018153970A1 (en) * 2017-02-24 2018-08-30 Bayer Pharma Aktiengesellschaft Solid forms of 2-[(3r)-3-methylmorpholin-4-yl]-4-(1-methyl-1h-pyrazol-5-yl)-8-(1h-pyrazol-5-yl)-1,7-naphthyridine

Also Published As

Publication number Publication date
DK3841101T3 (da) 2023-07-31
CO2021001892A2 (es) 2021-03-08
US20210253573A1 (en) 2021-08-19
PE20210862A1 (es) 2021-05-18
PT3841101T (pt) 2023-07-25
RS64362B1 (sr) 2023-08-31
IL280878A (en) 2021-04-29
CA3110394A1 (en) 2020-02-27
ES2950825T3 (es) 2023-10-13
LT3841101T (lt) 2023-06-26
EP3841101A1 (en) 2021-06-30
JP2021535122A (ja) 2021-12-16
JP7422741B2 (ja) 2024-01-26
MX2021002132A (es) 2021-04-28
AU2019324521A1 (en) 2021-03-11
KR20210049845A (ko) 2021-05-06
SI3841101T1 (sl) 2023-07-31
BR112021001309A2 (pt) 2021-04-27
EP3841101B1 (en) 2023-05-03
HRP20230611T1 (hr) 2023-09-15
CN112823158B (zh) 2023-08-15
WO2020039025A1 (en) 2020-02-27
UA128407C2 (uk) 2024-07-03
PL3841101T3 (pl) 2023-08-21
HUE062332T2 (hu) 2023-10-28
FI3841101T3 (fi) 2023-07-28
SG11202101011RA (en) 2021-02-25
CN112823158A (zh) 2021-05-18
JOP20210032A1 (ar) 2021-02-23

Similar Documents

Publication Publication Date Title
CL2021000454A1 (es) Método para preparar 2-[(3r)-3--metilmofolin--4-il]-4-(1-metil-1h-pirazol-5-il)-8-(1h-pirazol-5-il)-1,7-naftiridina
CL2020001547A1 (es) Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa.
ECSP19077553A (es) Oxadiazoles fungicidas
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
EA201891396A1 (ru) Способ получения 2-[4-(4-хлорфенокси)-2-(трифторметил)фенил]-1-(1,2,4-триазол-1-ил)пропан-2-ола
CR20170316A (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
BR112015016446A2 (pt) processo para a preparação dos compostos de fórmula e de um composto de triazol de fórmula, solução aquosa, utilização da solução aquosa, forma cristalina, composição agroquímica, utilização das formas cristalinas e método para o combate dos fungos nocivos
PE20141303A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
EA201792067A1 (ru) Противогрибковые соединения и способы получения
UY32142A (es) Preparación de una quinoliniloxidifenilciclopropanodicarboxamida
CO6700837A2 (es) Proceso de elaboración para derivados de prrimidina
MX2016007128A (es) Compuestos del receptor 6 de quimiocina (ccr6).
CL2020001047A1 (es) Derivados de imidazol condensado sustituidos por grupos de hidroxia terciaria como inhibidores pi3k-gamma.
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
CL2020001589A1 (es) Proceso para la preparación de derivados de quinolina.
MX2020002449A (es) Nuevos compuestos heterociclicos fungicidas.
MA50093B1 (fr) Composé pentacyclique
BR112021022538A2 (pt) Processos para preparar compostos de aminopirimidina
MX2018004055A (es) Compuestos de imino con un sustituyente de 2-cloropirimidin-5-ilo como agentes de control de plagas.
CU20200047A7 (es) Compuestos de alquinileno sustituidos como agentes anticancerígenos
UY33635A (es) ?imidazoles fungicidas?.
CO6700844A2 (es) Nuevas formas cristalinas del ácido (e)-3-(2-(1-((2-(5-bromo-pirimidin-2-il)-3- ciclopentil-1 metil-1h indol-6-carbonil)-amino)-ciclobutil-3-metil-3h-bacimidazol-5-)-acrílicos como inhibidores de vhc
CL2022001464A1 (es) Polimorfos del compuesto antifúngico de triazol pc945
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера